Clinical Trial Update: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer [Phase 3]

View source ↗

Summary

Phase 3 rollover study of Alectinib in ALK-positive or RET-positive cancers is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Cancer
• Ret-rearranged Cancer

Drugs mentioned

• Alecensa (alectinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING